Xencor Inc (NASDAQ:XNCR) VP John R. Desjarlais sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $40.69, for a total transaction of $1,424,150.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of XNCR stock traded down $1.88 during trading hours on Thursday, reaching $39.42. 1,814 shares of the stock traded hands, compared to its average volume of 395,400. Xencor Inc has a 1-year low of $27.75 and a 1-year high of $48.38. The business has a fifty day moving average price of $42.81 and a 200 day moving average price of $35.36. The company has a quick ratio of 8.27, a current ratio of 8.27 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $2.30 billion, a PE ratio of -30.11 and a beta of 1.39.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.15. Xencor had a net margin of 28.46% and a return on equity of 8.40%. The business had revenue of $19.49 million for the quarter, compared to analyst estimates of $7.58 million. Research analysts expect that Xencor Inc will post 0.05 earnings per share for the current fiscal year.
A number of analysts recently commented on XNCR shares. ValuEngine upgraded shares of Xencor from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Wedbush boosted their target price on shares of Xencor from $43.00 to $54.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. They noted that the move was a valuation call. Mizuho reiterated a “buy” rating and issued a $52.00 target price on shares of Xencor in a report on Monday, July 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $40.00 target price on shares of Xencor in a report on Sunday, May 12th. Finally, Guggenheim downgraded shares of Xencor from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Xencor has a consensus rating of “Buy” and a consensus price target of $45.57.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: Stock Portfolio Tracker
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.